Drugs / STR04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06910384 | Aug → Dec 2025 | amyotrophic lateral sclerosis | New England Cell Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STR04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06910384 ↗ |
| Modality | Cell therapy | “autologous bone-marrow-derived mesenchymal stem cells” NCT06910384 ↗ |
| Route | Intravenous | “STR04 administered intravenously” NCT06910384 ↗ |